Clinical trials
Polyarticular Juvenile Idiopathic Arthritis clinical trials
Below are recruiting polyarticular juvenile idiopathic arthritis clinical trials, each written for real people, not researchers. We’re tracking 6 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06654882RecruitingPhase 3
Switching medications after first treatment fails in juvenile arthritis
This study tests different medication sequences for children and teens with polyarticular juvenile idiopathic arthritis (JIA) who still have moderate or high disease activity after at least 3 months on their first tumor necrosis factor inhibitor (TNFi) therapy. The goal is to find the best next step to control symptoms and improve quality of life.
San Francisco, CaliforniaAges 2–17 - NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07554495RecruitingPhase 3
Filgotinib for moderate to severe polyarticular juvenile arthritis
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
LeuvenAges 8–18 - NCT07386587Enrolling by invitationPhase 3
Methotrexate plus etanercept for juvenile arthritis
This study compares methotrexate alone versus methotrexate combined with etanercept to see which works better for children with polyarticular juvenile idiopathic arthritis. The goal is to help children achieve low disease activity quickly.
Lahore, Punjab ProvinceAges 2–16 - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17
Hear when a new Polyarticular Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for polyarticular juvenile idiopathic arthritis?
- Yes. Clin2 currently lists 6 recruiting polyarticular juvenile idiopathic arthritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a polyarticular juvenile idiopathic arthritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a polyarticular juvenile idiopathic arthritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.